Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | ATP4A | P20648 | 1/20 | 0.36 |
| ▸ | ATP4B | P51164 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093561 | 0.87 | CYP3A4 (0.45) | ADRA2BADRA2CPOLBKDM4EUSP2 | |
| SCHEMBL10407894 | 0.85 | LIPG (0.52) | POLB | |
| Hydrochloric Acid SCHEMBL8801544 | 0.85 | CYP3A4 (0.44) | ADRA2BADRA2CPOLBKDM4EUSP2 | |
| SCHEMBL22535153 | 0.84 | L3MBTL1 (0.43) | POLBKDM4EUSP2ALDH1A1MAPT | |
| SCHEMBL13813554 | 0.84 | ADRA2B (0.46) | ADRA2BADRA2CKDM4EALDH1A1MAPT | |
| SCHEMBL4093510 | 0.84 | LIPG (0.55) | — | |
| SCHEMBL4089467 | 0.84 | LIPG (0.55) | — | |
| SCHEMBL11349035 | 0.84 | LIPG (0.55) | — | |
| SCHEMBL4083405 | 0.84 | LIPG (0.55) | — | |
| SCHEMBL4079740 | 0.84 | LIPG (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285769-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE AMINES | Generics [UK] Limited (GB) | 2011-02-23 | — | — | EP | claimed |
| WO-2009147430-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE AMINES | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| EP-0344675-A2 | Method for the production of selegiline hydrochloride | FARMAKON (CS) | 1989-12-06 | — | — | EP | claimed |
| WO-2024124463-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | LUMIPHORE, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | LUMIPHORE, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2017-09-14 | — | — | US | disclosed |
| CN-103732632-B | Method for producing olefin block polymer using Group 4 transition metal complex | 住友化学株式会社 | 2017-07-07 | — | — | CN | disclosed |
| US-9656956-B2 | Benzene, pyridine, and pyridazine derivatives | ESANEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| CN-1537873-A | Polyaddition catalyst component, polyaddition catalyst and process for preparing addition polymer | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| CN-1537874-A | Polyaddition catalyst component, polyaddition catalyst and method for preparing addition polymer | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| CN-1537872-A | Polyaddition catalyst component, polyaddition catalyst, and method for preparing addition polymer | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| CN-1537871-A | Polyaddition catalyst component polyaddition catalyst and pruess for producing addition polymer | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| CN-1532209-A | Contact product, catalytic component and addition polymerizing cathlyst and method for producing addition polymer | 住友化学工业株式会社 | 2004-09-29 | — | — | CN | disclosed |
| CN-1530378-A | Catalyst component for polyaddition, catalyst and method for producing addition polymer | ס�ѻ�ѧ��ҵ��ʽ���� | 2004-09-22 | — | — | CN | disclosed |
| CN-1422286-A | Modified particle, support, catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL CO (JP) | 2003-06-04 | — | — | CN | disclosed |
| CN-1408738-A | Catalytic component for addition polymerization, process for producing addition polymerization and process for producing addition polymer | SUMITOMO CHEMICAL CO (JP) | 2003-04-09 | — | — | CN | disclosed |
| CN-1306011-A | Polyaddition catalyst component, polyaddition catalyst and method for preparing addition polymer | SUMITOMO CHEMICAL CO (JP) | 2001-08-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | ADRA2B 3736/4885ADRA2C 3897/4885POLB 1722/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | ADRA2B 4143/4885ADRA2C 4307/4885POLB 1589/4885 |
| US-20180194766-A1 | MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF | TFRC, CLTC, SLC39A3 | ADRA2B 4667/4885ADRA2C 4256/4885POLB 1462/4885 |
| US-20170260174-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | ADRA2B 913/4885ADRA2C 1240/4885POLB 2240/4885 |
| US-10239878-B2 | Macrocyclic ligands with pendant chelating moieties and complexes thereof | TFRC, CLTC, SLC39A3 | ADRA2B 4667/4885ADRA2C 4256/4885POLB 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.